{"id":3897,"date":"2026-10-24T09:00:00","date_gmt":"2026-10-24T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3897"},"modified":"2026-10-24T15:38:44","modified_gmt":"2026-10-24T19:38:44","slug":"saturday-rounds-week-of-october-17-23-2026","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3897","title":{"rendered":"Saturday Rounds: Week of October 17\u201323, 2026"},"content":{"rendered":"

\"\"<\/p>\n

A cure endpoint, a rebound, and milestone-heavy deals.<\/strong><\/p>\n

Weekly Biotech Signal Review \u00b7 Completed reporting week: October 17\u2013October 23, 2026 \u00b7 Published October 24, 2026<\/p>\n

Report at a glance:<\/strong> The FDA approved the first antisense drug for chronic hepatitis B on a functional-cure endpoint, XBI rebounded 3.62% while SPY slipped, and buyers paid $1.73 billion upfront or at closing for assets that are mostly early or preclinical.<\/p>\n

The Lede<\/h3>\n

On October 20 the FDA approved GSK’s Hibsago (bepirovirsen), the first antisense oligonucleotide for chronic hepatitis B, for adults without cirrhosis who are on nucleos(t)ide analogue therapy with suppressed HBV DNA and HBsAg of 3,000 IU\/mL or less. In the two Phase 3 B-Well trials, functional cure at week 72 was 20% and 19% versus none on placebo. It turns RNA medicine from long-term suppression into a fixed-duration course with a measurable off-treatment endpoint, though most treated patients did not reach functional cure. The week also brought a second FDA accelerated approval (dostarlimab in dMMR\/MSI-H rectal cancer), a positive Phase 3 in a CLDN18.2 ADC, a failed primary endpoint at Elicio, and an XBI rebound of 3.62%.<\/p>\n\n\n\n\n\n
Signal Importance<\/th>\nSignal Direction<\/th>\nConfidence in Facts<\/th>\nConfidence in Interpretation<\/th>\n<\/tr>\n<\/thead>\n
5 \/ 5<\/td>\nPositive, with mixed evidence<\/td>\nHigh<\/td>\nModerate<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Weekly validation gate: importance is 5\/5 because a first-in-class approval, a second accelerated approval, a Phase 3 survival win in China-originated science, a $1.3 billion acquisition and a proposed U.S. outbound-investment rule landed together. Interpretation is moderate because key trial details (full ESMO data, boxed-warning content) were not fully retrievable.<\/em><\/p>\n

Signal of the Week: Hibsago and a Finite Path to HBV Functional Cure<\/h3>\n

Hibsago pairs a randomized Phase 3 package with a legible endpoint: pooled functional cure of 19% (26% among patients with baseline HBsAg of 1,000 IU\/mL or less) versus none on placebo, delivered as a fixed-duration subcutaneous course. The FDA also authorized a companion HBsAg assay for patient selection. The competitive implication is pressure on indefinite nucleos(t)ide suppression and a regulatory precedent for finite RNA-directed HBV regimens.<\/p>\n

The strongest counterargument is narrow uptake. The label is restricted to a biomarker-defined, non-cirrhotic population, and coverage of the approval notes boxed-warning and monitoring requirements (we could not retrieve the warning text). Most treated patients still did not achieve functional cure, and durability beyond the trial follow-up remains to be shown.<\/p>\n

The Week in Five<\/h3>\n

Regulatory<\/strong> \u2014 Beyond Hibsago, the FDA granted accelerated approval on October 19 to GSK’s dostarlimab (Jemperli) for stage II\/III MSI-H\/dMMR locally advanced rectal cancer, four months ahead of the goal date. It rests on the single-arm AZUR-1 study: a 12-month clinical complete response rate of 47% in 116 centrally evaluable patients (investigator-assessed rates were higher), with duration of response and recurrence still unknown.<\/p>\n

Clinical<\/strong> \u2014 Takeda and Innovent reported on October 23 that Phase 3 G-HOPE-001 of arcotatug tavatecan (CLDN18.2 ADC) met both dual primary endpoints, OS and PFS, versus physician’s choice in previously treated CLDN18.2-positive gastric cancer (exact survival medians were not retrievable; Grade 3+ anemia 20.4%). Disc Medicine’s Phase 3 APOLLO of bitopertin in EPP\/XLP (n=183) met all endpoints, with a 41.4% PPIX reduction and 12.2 more pain-free hours in light versus placebo; an NDA resubmission is planned by end-2026. Elicio’s AMPLIFY-7P, presented at ESMO with a Nature Medicine paper, had already missed its primary DFS endpoint in ITT (HR 0.85, n=144, announced in June); the October data are post-hoc R0 subgroup results (HR 0.65). Merck and Moderna’s INTerpath-001 (topline August 19: RFS HR 0.58, 2-year RFS 82.2% versus 70.0%) was presented in detail at ESMO.<\/p>\n

Deals<\/strong> \u2014 Merck KGaA agreed to buy Silence Therapeutics at $20 per ADS (about $1.3 billion equity value, a roughly 130% premium; close expected Q1 2027). Gilead will pay $1.275 billion in cash at closing for PepStar’s Phase 1 oral IL-23R program (HCXT-2001). Hansoh\u2013Roche: $400 million upfront, a $110 million first-anniversary payment and more than $15 billion in potential milestones. Zymeworks licensed the DLL3 trispecific ZW209 to Roche ($55 million upfront, $40 million at Phase 1b start, up to $718 million more; HSR clearance pending).<\/p>\n

Platform<\/strong> \u2014 The week’s platform news was transactional: Silence’s siRNA capability to Merck KGaA, Hansoh’s ADC platform to Roche, and a Phase 1 oral macrocyclic peptide to Gilead. The reference file’s CAR-T naive-fraction analysis and other papers could not be independently verified and are not reported here.<\/p>\n

China and policy<\/strong> \u2014 Arcotatug (Innovent) and the Hansoh alliance underline China as an asset origin. On October 22 the U.S. Treasury proposed adding biotechnology to its outbound-investment program under the COINS Act, which would bar U.S. equity, convertible-debt, joint-venture and similar investments in covered Chinese biotech companies while generally leaving conventional licensing (upfronts, milestones, royalties) outside the restrictions; the joint-venture definition is vague, and comments are due December 7.<\/p>\n

The Analyst’s Take<\/h3>\n

Observed pattern: late-stage evidence strengthened (Hibsago, arcotatug, bitopertin, INTerpath-001), and one visible miss (Elicio’s primary endpoint) carried a subgroup rescue story. Buyers also paid for assets well short of that bar: Gilead’s $1.275 billion went to a Phase 1 peptide and Roche’s Zymeworks deal covers a Phase 1-entry trispecific.<\/p>\n

Explicit inference: buyers are paying for platform access, target scarcity and regional discovery productivity, shifting most clinical risk into contingent payments. The Hansoh alliance puts more than $15 billion in milestones against $510 million of upfront and anniversary payments, and Zymeworks’ headline of $813 million is 12% committed. Competing interpretation: large balance sheets and portfolio gaps can support aggressive prices without broad confidence in the modalities.<\/p>\n

The thesis strengthens if early assets show human PK\/PD and tolerability preserving their intended advantage, and if randomized data reproduce across geography. It weakens if Hibsago’s monitoring burden narrows uptake, if CLDN18.2 benefit does not travel beyond the trial population, or if the proposed Treasury rule reaches licensing structures despite its stated carve-out.<\/p>\n

Evidence Classification<\/h3>\n\n\n\n\n\n
Verified facts<\/th>\nCompany claims<\/th>\nExplicit inference<\/th>\n<\/tr>\n<\/thead>\n
FDA approvals of Hibsago and dostarlimab, deal terms (Silence, PepStar, Hansoh, Zymeworks), Lycia’s IPO pricing, the Treasury proposal and the XBI\/IBB\/SPY closes were checked against FDA, company releases, SEC filings and named trade press.<\/td>\nAPOLLO, G-HOPE-001 and INTerpath-001 results are sponsor-reported topline or conference data; Elicio’s subgroup and baseline-imbalance arguments are post-hoc company framing.<\/td>\n“Buyers pay for optionality while pushing risk into milestones” and the read-through from Treasury and MOFCOM proposals to deal structures are interpretations.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Market & Capital Pulse<\/h3>\n

Observed market facts<\/strong><\/p>\n

Measurement window: Friday, October 16 close to Friday, October 23 close. XBI rose 3.62% (144.32 to 149.54), IBB rose 2.85% (201.99 to 207.74) and SPY fell 0.43% (763.25 to 759.97), so XBI outperformed SPY by about 4.05 points. XBI’s path was uneven: +2.45% on Monday and +3.64% on Tuesday, then three down days (\u22120.30%, \u22120.75%, \u22121.38%). The reference file’s Nasdaq and Russell 2000 weekly figures were not verified and are not reported.<\/p>\n

Capital and strategic appetite<\/strong><\/p>\n

Lycia Therapeutics priced an upsized $317.5 million IPO at $18.00, the top of its range (17.64 million shares; LYTAC protein-degradation platform; lead programs in food allergy and Graves’ disease, both Phase 1), and rose roughly 32\u201334% on its first trading day. Verified private rounds were Nouscom’s $135 million Series D (\u20ac120 million; Lynch-syndrome cancer-interception program) and Pathos AI’s $237 million Series E (led by Bristol Myers Squibb, about $3 billion post-money), together $372 million. The reference file’s $200 million Star Therapeutics round could not be confirmed and is excluded. No material biotechnology workforce reduction was verified this week.<\/p>\n

Inference, not causation:<\/strong> an XBI rebound, an upsized platform IPO and large private rounds suggest capital for differentiated science and experienced teams, but one IPO and a few concentrated rounds do not establish a broad reopening, and the Treasury proposal could redirect cross-border financing structures.<\/p>\n

Deal Appetite and Restructuring<\/h3>\n

Four deals were verified. Upfront or at-closing cash totaled $1.73 billion across Gilead ($1.275 billion), Hansoh ($400 million) and Zymeworks ($55 million), kept separate from Merck KGaA’s $1.3 billion equity value for Silence. Additional near-term payments were $150 million (Hansoh’s $110 million anniversary payment and Zymeworks’ $40 million at Phase 1b start). Further milestones exceed $15.7 billion, almost all from Hansoh. Silence’s lead program is divesiran (polycythemia vera); the scheme of arrangement is expected to complete in Q1 2027.<\/p>\n

No new restructuring was verified. Leadership: the reference file’s Foundation Medicine CMO appointment could not be confirmed and is not reported.<\/p>\n

By the Numbers<\/h3>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Category<\/th>\nVerified count or value<\/th>\nScope note<\/th>\n<\/tr>\n<\/thead>\n
FDA approvals<\/td>\n2<\/td>\nHibsago (Oct 20); dostarlimab accelerated approval, rectal cancer (Oct 19).<\/td>\n<\/tr>\n
Other regulatory \/ policy actions<\/td>\n1<\/td>\nU.S. Treasury proposed outbound-investment rule for biotechnology (Oct 22). The reference file’s EC authorization and filing acceptance were not verified.<\/td>\n<\/tr>\n
Clinical readouts verified<\/td>\n4 new + 1 presented<\/td>\nG-HOPE-001 (met); APOLLO (met); AMPLIFY-7P (primary missed, data presented); AZUR-1 (single-arm, approval basis); INTerpath-001 presented at ESMO (topline Aug 19).<\/td>\n<\/tr>\n
Deals<\/td>\n4<\/td>\nMerck KGaA\u2013Silence; Gilead\u2013PepStar; Hansoh\u2013Roche; Zymeworks\u2013Roche.<\/td>\n<\/tr>\n
Upfront \/ at closing<\/td>\n$1.73B<\/td>\nGilead $1.275B; Hansoh $400M; Zymeworks $55M. Excludes Merck KGaA’s $1.3B equity value.<\/td>\n<\/tr>\n
Near-term payments \/ milestones<\/td>\n$150M \/ >$15.7B<\/td>\nHansoh anniversary $110M and Zymeworks Phase 1b $40M; milestones mostly Hansoh (>$15B) and Zymeworks ($718M).<\/td>\n<\/tr>\n
Private rounds<\/td>\n2 \/ $372M<\/td>\nNouscom $135M Series D; Pathos AI $237M Series E. Star Therapeutics ($200M) not verified.<\/td>\n<\/tr>\n
IPOs<\/td>\n1 \/ $317.5M<\/td>\nLycia; greenshoe of about 2.6M shares excluded.<\/td>\n<\/tr>\n
Restructurings<\/td>\n0<\/td>\nNone verified.<\/td>\n<\/tr>\n
Leadership changes<\/td>\n0<\/td>\nNone verified.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Counting notes: the reference file’s peer-reviewed-paper count (11), clinical-readout count (12) and several named readouts (brepocitinib uveitis, Kyverna, Iovance, ORIC, Korro, ROR2 AML CAR-T) were not independently verified in this edition and are excluded.<\/em><\/p>\n

Watching Next Week<\/h3>\n

Resolution of last week’s calendar:<\/strong> the bepirovirsen PDUFA that trackers placed on October 26 was resolved early, with FDA approval on October 20. ESMO opened October 23 with the INTerpath-001 and G-HOPE-001 data; we did not review the Tango or Immatics presentations for this edition.<\/p>\n\n\n\n\n\n\n\n\n\n\n
Date<\/th>\nCatalyst<\/th>\nEvidence status<\/th>\n<\/tr>\n<\/thead>\n
Through Oct 27<\/td>\nESMO Congress 2026, Madrid<\/td>\nConfirmed (Oct 23\u201327).<\/td>\n<\/tr>\n
Wed Oct 28<\/td>\nGSK Q3 2026 results<\/td>\nConfirmed date; sources give 3:00 a.m. and 8:00 a.m. ET for the call, so check GSK’s page. First commercial framing for Hibsago.<\/td>\n<\/tr>\n
Thu Oct 29<\/td>\nMerck Q3 2026 earnings call, 9:00 a.m. ET<\/td>\nConfirmed on Merck’s investor page.<\/td>\n<\/tr>\n
Fri Oct 30<\/td>\nINO-3107 (Inovio) PDUFA, recurrent respiratory papillomatosis<\/td>\nConfirmed target date; the FDA’s acceptance letter questioned eligibility for accelerated approval.<\/td>\n<\/tr>\n
Fri Oct 30<\/td>\nFDA Dermatologic and Ophthalmic Drugs Advisory Committee (atropine 0.01%, pediatric myopia; Sydnexis)<\/td>\nConfirmed on FDA calendar.<\/td>\n<\/tr>\n
Dec 7<\/td>\nComment deadline, Treasury outbound-investment proposal<\/td>\nReported by trade press.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

What Would Change Our View<\/h3>\n

Upgrade<\/strong> \u2014 Human PK\/PD and tolerability data show the newly acquired early programs (PepStar, Zymeworks, Hansoh) achieve useful exposure without losing their convenience or safety advantage.<\/p>\n

Downgrade<\/strong> \u2014 Post-launch Hibsago monitoring burden or discontinuation narrows the eligible functional-cure population, or longer follow-up weakens durability of this week’s late-stage results.<\/p>\n

Falsify<\/strong> \u2014 Independent, geography-diverse trials fail to reproduce the week’s controlled effects, or the final Treasury rule reaches licensing deals despite its stated carve-out.<\/p>\n

Evidence Base<\/h3>\n

Sources are listed in order of first citation. Discrepancies versus the reference file used for this edition: the 10.2 versus 6.9 month OS figures for arcotatug could not be confirmed; Elicio’s primary-endpoint miss was first announced in June, with October bringing the ESMO data and Nature Medicine paper; INTerpath-001’s topline was August 19; the Star Therapeutics round, Foundation Medicine appointment, Nasdaq\/Russell 2000 figures, EC authorization, filing acceptance, 11-paper count and several single-arm readouts could not be confirmed and were excluded; the Oct 25 HARMONi-GI1 and Oct 26 Merck investor-event calendar items were not confirmed. Hibsago’s boxed-warning contents were not retrievable.<\/em><\/p>\n

    \n
  1. GSK, Hibsago (bepirovirsen) approved in the US for chronic hepatitis B<\/a><\/li>\n
  2. Pharmacy Times, FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B<\/a><\/li>\n
  3. FDA, FDA grants accelerated approval to dostarlimab for locally advanced rectal cancer<\/a><\/li>\n
  4. The ASCO Post, FDA Approves Dostarlimab for MSI-H\/dMMR Locally Advanced Rectal Cancer<\/a><\/li>\n
  5. Takeda, Arcotatug Tavatecan (TAK-921) Phase 3 Advanced Gastric Cancer Study<\/a><\/li>\n
  6. Innovent, 2026 ESMO LBA: Phase 3 Study of Arcotatug Tavatecan Met Dual Primary Endpoints<\/a><\/li>\n
  7. Disc Medicine, Success on All Endpoints in Phase 3 APOLLO Trial of Bitopertin (Oct 19, 2026)<\/a><\/li>\n
  8. Elicio Therapeutics, Late-Breaking AMPLIFY-7P Results at ESMO 2026 and Nature Medicine Publication<\/a><\/li>\n
  9. CancerNetwork, ELI-002 7P Misses Primary End Point in Phase 2 AMPLIFY-7P PDAC Study<\/a><\/li>\n
  10. Merck and Moderna, Phase 3 INTerpath-001 Met RFS and DMFS Endpoints (Aug 19, 2026)<\/a><\/li>\n
  11. Merck.com, INTerpath-001 Results at ESMO 2026 Presidential Symposium<\/a><\/li>\n
  12. Silence Therapeutics, Agreement to be Acquired by Merck KGaA (Business Wire, Oct 19, 2026)<\/a><\/li>\n
  13. Fierce Biotech, Merck KGaA buys Silence in $1.3B deal<\/a><\/li>\n
  14. Gilead Sciences, Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001<\/a><\/li>\n
  15. Hansoh Pharma, Strategic Collaboration and License Agreement with Roche<\/a><\/li>\n
  16. Drug Discovery Trends, Roche\u2013Hansoh ADC deal: $400M upfront, $15B+ milestones<\/a><\/li>\n
  17. Zymeworks, Exclusive Global License and Collaboration Agreement with Roche for ZW209<\/a><\/li>\n
  18. STAT, Treasury proposes major restrictions to U.S. investment in Chinese biotech sector<\/a><\/li>\n
  19. BioSpace, US explores China biotech restrictions, exempts licensing deals<\/a><\/li>\n
  20. BioSpace, Lycia Therapeutics Announces Pricing of Upsized Initial Public Offering<\/a><\/li>\n
  21. Investing.com, Lycia Therapeutics surges in debut following upsized $317.5M IPO<\/a><\/li>\n
  22. Fierce Biotech, Fundraising Tracker ’26 (Nouscom $135M Series D)<\/a><\/li>\n
  23. BioPharmaWatch, Pathos AI Raises $237 Million Series E<\/a><\/li>\n
  24. Merck, Q3 2026 Earnings Call<\/a><\/li>\n
  25. MarketBeat, GSK Q3 2026 Earnings Report on 10\/28\/2026<\/a><\/li>\n
  26. Yahoo Finance, Inovio Spotlights INO-3107 BLA Acceptance, FDA Talks Ahead of Oct. 30 PDUFA Date<\/a><\/li>\n
  27. FDA, Dermatologic and Ophthalmic Drugs Advisory Committee, Oct 30, 2026<\/a><\/li>\n
  28. StockAnalysis.com, XBI price history (Oct 23, 2026)<\/a><\/li>\n
  29. StockAnalysis.com, IBB price history (Oct 23, 2026)<\/a><\/li>\n
  30. StockAnalysis.com, SPY price history (Oct 23, 2026)<\/a><\/li>\n<\/ol>\n

    Until next Saturday: follow the evidence, not the noise.<\/p>\n","protected":false},"excerpt":{"rendered":"

    A cure endpoint, a rebound, and milestone-heavy deals. Weekly Biotech Signal Review \u00b7 Completed reporting week: October 17\u2013October 23, 2026 \u00b7 Published October 24, 2026 Report at a glance: The FDA approved the first…<\/p>\n","protected":false},"author":1,"featured_media":3898,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[250,251,249],"class_list":["post-3897","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-weekly-market-insight","tag-biotech-markets","tag-ma","tag-weekly-digest"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3897","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3897"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3897\/revisions"}],"predecessor-version":[{"id":3899,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3897\/revisions\/3899"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3898"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3897"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3897"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3897"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}